Perspective
Our work in Perspective
-
Value-Based Drug Pricing Makes Sense, But is Difficult to Pull Off
There are challenges of value-based pricing and health technology assessments.
Categorized in -
Allowing States to Define “Essential Health Benefits” Could Weaken ACA Protections Against Catastrophic Costs for People with Employer Coverage Nationwide
This post addresses the new MacArthur Amendment specifically and provides more detail on why waivers in one state could have effects elsewhere.
Categorized in -
Value-Based Pricing For Pharmaceuticals In The Trump Administration
The change in administration is an opportune moment for CMS to assume a leadership role with respect to value-based pricing.
Categorized in -
A Good Deal For Eliminating Hepatitis C: Saving Money And Lives
Hepatitis C kills more than 20,000 Americans each year. A recent consensus committee of the National Academies of Sciences, Engineering, and Medicine proposed a novel strategy to improve access to hepatitis C medicines.
Categorized in -
To Promote Stability in Health Insurance Exchanges, End the Uncertainty Around Cost-Sharing and Other Rules
While it is unclear whether the changes included in the CMS rule will have a small positive or negative impact on market stability, it is clear that the impact pales in comparison to the instability caused by the lack of commitment to fund the ACA’s cost-sharing reduction subsidies or to enforce the individual mandate.
Categorized in -
How Expanding the Role of Pharmacists Lowered Readmissions and Costs in one California Community
Technology and data can help pharmacists provide services required to manage life-long, outpatient drug therapies.
Categorized in -
Viewpoint – Making Health Care Markets Work: Competition Policy for Health Care
The authors propose a new competition policy for health care that involves multiple federal agencies in addition to the antitrust enforcement agencies, state governments, and private stakeholders.
Categorized in -
New Changes to Essential Benefits in the GOP Health Bill Could Jeopardize Protections Against Catastrophic Costs, Even for People with Job-Based Coverage
Weakening essential health benefit standards could also have important negative consequences for the coverage offered by employers of all sizes because it would weaken the ACA’s guarantee of protection against catastrophic costs.
Categorized in -
Tackling the Opioid Crisis with Compassion, New Ways to Reduce Use and Treatment
This piece explains how we arrived at the current opioid crisis, policies that have been tried thus far, and options to address the crisis moving forward.
Categorized in -
Sky-High Drug Prices for Rare Diseases Show Why Orphan Drug Act Needs Reform
The Orphan Drug Act (ODA) was passed 34 years ago to promote development of drugs aimed at diseases that afflict small groups, typically under 200,000 people. However, the nature of drug development has changed. Our researchers see an opportunity for improvement.
Categorized in